However, without controlled studies it remains unclear whether the degree of weight loss, the consistency of results, or the side effect profile matches what has been observed in clinical trials of FDA approved products
Solutions for Losing While Living
Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Semaglutide Safety Information The most common side effects of semaglutide are nausea, diarrhea, and vomiting.[1,2] Other frequent side effects include headache, fatigue, upset stomach, dizziness, belching, abdominal distention, hypoglycemia in type 2 diabetes, and flatulence
Maximum recommended dose